Beyond BCG: Tumor Board Insights on Managing Unresponsive NMIBC With Novel Treatments

Ashish Kamat, MD, MBBS; Sam Chang, MD, MBA; Bogdana Schmidt, MD, MPH; and Katie Murray, DO, MS, discuss how management of non–muscle-invasive bladder cancer (NMIBC) requires careful risk stratification, standardized BCG therapy protocols, consideration of alternative treatments for BCG-unresponsive disease, gender-specific approaches, and specialized care for younger patients to improve outcomes and quality of life.